{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:20:32Z","timestamp":1787289632224,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Rovi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12325-022-02299-8","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T06:03:42Z","timestamp":1662012222000},"page":"4875-4891","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-7931","authenticated-orcid":false,"given":"Cecilio","family":"\u00c1lamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"1","key":"2299_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","volume":"150","author":"R Tandon","year":"2013","unstructured":"Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150(1):3\u201310.","journal-title":"Schizophr Res"},{"issue":"12","key":"2299_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050225","volume":"5","author":"S Fazel","year":"2008","unstructured":"Fazel S, Khosla V, Doll H, Geddes J. The prevalence of mental disorders among the homeless in western countries: systematic review and meta-regression analysis. PLoS Med. 2008;5(12): e225.","journal-title":"PLoS Med"},{"key":"2299_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234\u201358.","journal-title":"Drug Alcohol Depend"},{"issue":"10211","key":"2299_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(19)32316-5","volume":"394","author":"O Plana-Ripoll","year":"2019","unstructured":"Plana-Ripoll O, Pedersen CB, Agerbo E, et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet. 2019;394(10211):1827\u201335.","journal-title":"Lancet"},{"issue":"3","key":"2299_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jamapsychiatry.2017.4437","volume":"75","author":"GE Simon","year":"2018","unstructured":"Simon GE, Stewart C, Yarborough BJ, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiat. 2018;75(3):254\u201360.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"2299_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.rpsm.2018.03.006","volume":"12","author":"C Arango","year":"2019","unstructured":"Arango C, Baeza I, Bernardo M, et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment (Engl Ed). 2019;12(2):92\u2013105.","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)"},{"issue":"9831","key":"2299_CR7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063\u201371.","journal-title":"Lancet"},{"issue":"10039","key":"2299_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86\u201397.","journal-title":"Lancet"},{"issue":"5","key":"2299_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"2299_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/17425247.2016.1115479","volume":"13","author":"T Suzuki","year":"2016","unstructured":"Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opin Drug Deliv. 2016;13(2):253\u201364.","journal-title":"Expert Opin Drug Deliv"},{"issue":"10","key":"2299_CR11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909.","journal-title":"J Clin Psychiatry"},{"issue":"2\u20133","key":"2299_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","volume":"176","author":"D Novick","year":"2010","unstructured":"Novick D, Haro JM, Su\u00e1rez D, P\u00e9rez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2\u20133):109\u201313.","journal-title":"Psychiatry Res"},{"issue":"4","key":"2299_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00003088-198510040-00003","volume":"10","author":"MW Jann","year":"1985","unstructured":"Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet. 1985;10(4):315\u201333.","journal-title":"Clin Pharmacokinet"},{"issue":"9657","key":"2299_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31\u201341.","journal-title":"Lancet"},{"issue":"4","key":"2299_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1212\/WNL.0000000000001788","volume":"85","author":"K Tifratene","year":"2015","unstructured":"Tifratene K, Robert P, Metelkina A, Pradier C, Dartigues JF. Progression of mild cognitive impairment to dementia due to AD in clinical settings. Neurology. 2015;85(4):331\u20138.","journal-title":"Neurology"},{"issue":"4","key":"2299_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40261-021-01000-1","volume":"41","author":"C Rognoni","year":"2021","unstructured":"Rognoni C, Bertolani A, Jommi C. Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects. Clin Drug Investig. 2021;41(4):303\u201319.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"2299_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/ijnp\/pyab071","volume":"25","author":"D Najarian","year":"2022","unstructured":"Najarian D, Sanga P, Wang S, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238\u201351.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"2299_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/15622975.2012.739708","volume":"14","author":"A Hasan","year":"2013","unstructured":"Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2\u201344.","journal-title":"World J Biol Psychiatry"},{"key":"2299_CR19","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1192\/bjp.195.52.s63","volume":"52","author":"JM Kane","year":"2009","unstructured":"Kane JM, Garc\u00eda-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S63\u20137.","journal-title":"Br J Psychiatry Suppl"},{"issue":"7","key":"2299_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiat. 2017;74(7):686\u201393.","journal-title":"JAMA Psychiat"},{"issue":"Suppl 3","key":"2299_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"2299_CR22","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","volume":"44","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mehtala J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381\u20137.","journal-title":"Schizophr Bull"},{"key":"2299_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","volume":"197","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274\u201380.","journal-title":"Schizophr Res"},{"key":"2299_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/NDT.S326299","volume":"18","author":"L Citrome","year":"2022","unstructured":"Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Management of schizophrenia with long-acting injectable antipsychotic medications: an assessment of the educational needs of clinicians. Neuropsychiatr Dis Treat. 2022;18:111\u201323.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"2299_CR25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s12325-017-0507-x","volume":"34","author":"E Biagi","year":"2017","unstructured":"Biagi E, Capuzzi E, Colmegna F, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther. 2017;34(5):1036\u201348.","journal-title":"Adv Ther"},{"key":"2299_CR26","doi-asserted-by":"crossref","unstructured":"Correll CU, Lauriello J. Using long-acting injectable antipsychotics to enhance the potential for recovery in schizophrenia. J Clin Psychiatry. 2020;81(4):MS19053AH5C.","DOI":"10.4088\/JCP.MS19053AH5C"},{"key":"2299_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/1471-244X-13-340","volume":"13","author":"PM Llorca","year":"2013","unstructured":"Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340.","journal-title":"BMC Psychiatry"},{"issue":"1 Suppl","key":"2299_CR28","first-page":"1","volume":"35","author":"M Roca","year":"2007","unstructured":"Roca M, Ca\u00f1as F, Olivares J, Rodr\u00edguez A, Giner J. Treatment adherence in schizophrenia. Spanish clinical consensus. Actas Esp Psiquiatr. 2007;35(1 Suppl):1\u20136.","journal-title":"Actas Esp Psiquiatr"},{"key":"2299_CR29","unstructured":"National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. https:\/\/www.nice.org.uk\/guidance\/cg178. Accessed 6 Jun 2022."},{"key":"2299_CR30","unstructured":"Lehman AF, Libermen JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed: American Psychiatric Association; 2010."},{"issue":"3","key":"2299_CR31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.rpsm.2016.01.003","volume":"9","author":"PS Ramos","year":"2016","unstructured":"Ramos PS. Shared decision making in mental health: myths, barriers, and benefits. Rev Psiquiatr Salud Ment. 2016;9(3):175\u20136.","journal-title":"Rev Psiquiatr Salud Ment"},{"issue":"8","key":"2299_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40263-020-00735-3","volume":"34","author":"I Clark","year":"2020","unstructured":"Clark I, Taylor D. Newer formulations of risperidone: role in the management of psychotic disorders. CNS Drugs. 2020;34(8):841\u201352.","journal-title":"CNS Drugs"},{"issue":"1","key":"2299_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","volume":"35","author":"CU Correll","year":"2021","unstructured":"Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39\u201359.","journal-title":"CNS Drugs"},{"issue":"12","key":"2299_CR34","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.clinthera.2004.12.009","volume":"26","author":"ED Knox","year":"2004","unstructured":"Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther. 2004;26(12):1994\u20132002.","journal-title":"Clin Ther"},{"issue":"6","key":"2299_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/YIC.0000000000000139","volume":"31","author":"J Llaud\u00f3","year":"2016","unstructured":"Llaud\u00f3 J, Anta L, Ayani I, et al. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). Int Clin Psychopharmacol. 2016;31(6):323\u201331.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"2299_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41537-020-00127-y","volume":"6","author":"CU Correll","year":"2020","unstructured":"Correll CU, Litman RE, Filts Y, et al. Efficacy and safety of once-monthly Risperidone ISM\u00ae in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020;6(1):37.","journal-title":"NPJ Schizophr"},{"issue":"2","key":"2299_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/YIC.0000000000000203","volume":"33","author":"L Anta","year":"2018","unstructured":"Anta L, Llaud\u00f3 J, Ayani I, Mart\u00ednez J, Litman RE, Gutierro I. A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. Int Clin Psychopharmacol. 2018;33(2):79\u201387.","journal-title":"Int Clin Psychopharmacol"},{"key":"2299_CR38","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.2147\/DDDT.S332026","volume":"15","author":"DP Walling","year":"2021","unstructured":"Walling DP, Hassman HA, Anta L, et al. The steady-state comparative bioavailability of intramuscular risperidone ISM and oral risperidone: an open-label, one-sequence study. Drug Des Devel Ther. 2021;15:4371\u201382.","journal-title":"Drug Des Devel Ther"},{"key":"2299_CR39","doi-asserted-by":"crossref","unstructured":"Anta L, Mata E, Ochoa D\u00edaz de Monasterioguren L. Newer formulations of risperidone: remarks about risperidone ISM\u00ae. CNS Drugs. 2020;34(10):1087\u20138.","DOI":"10.1007\/s40263-020-00762-0"},{"key":"2299_CR40","unstructured":"ClinicalTrials.gov. Evaluation of IM letrozole ISM\u00ae pharmacokinetics, safety, and tolerability in healthy post-menopausal women (LISA-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03401320. Accessed 6 Jun 2022."},{"key":"2299_CR41","unstructured":"Farr\u00e9 M, Mat\u00ednez-Gonz\u00e1lez J, Cordero P, et al. A clinical trial to evaluate the pharmacokinetics, safety and tolerability of single doses of risperidone with the novel long-acting injectable technology ISM\u00ae in healthy volunteers. Eur Arch Psychiatry Clin Neurosci. 2011;261(Suppl 1):S57 (Abstract O-04\u2013005)."},{"issue":"8 Suppl","key":"2299_CR42","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.clinthera.2015.05.019","volume":"37","author":"J Winkler","year":"2015","unstructured":"Winkler J, Snoeck E, Llaud\u00f3 Garin J, Ayani I, Mart\u00ednez-Gonz\u00e1lez J, Gutierro AI. Population pharmacokinetic modeling and simulations of long-acting intramuscular risperidone ISM\u00ae. Clin Ther. 2015;37(8 Suppl):e3\u20134.","journal-title":"Clin Ther"},{"key":"2299_CR43","doi-asserted-by":"crossref","unstructured":"Litman RE, Filts Y, Pata M, et al., editors. P.0839 Risperidone ISM\u00ae effect size evaluation: post-hoc findings from the prisma-3 phase III study. 34th European College of Neuropsychopharmacology (ECNP); 2021 October 2\u20135th; Lisbon, Portugal.","DOI":"10.1016\/j.euroneuro.2021.10.698"},{"key":"2299_CR44","unstructured":"Litman R, Anta L, Mart\u00ednez J, Mart\u00ednez-Gonz\u00e1lez J, Litman RE, Correll C, editors. Personal and social functioning in patients with schizophrenia treated with once-monthly Risperidone ISM\u00ae. 8th European Conference on Schizophrenia Research (ECSR); 2021 September 23\u201325th; Berlin, Germany."},{"key":"2299_CR45","unstructured":"Correll C, Pata M, Litman RE, Naber D, editors. Risperidone ISM\u00ae efficacy in schizophrenia patients with severe psychotic symptoms during an acute exacerbation patients with severe psychotic symptoms. 8th European Conference on Schizophrenia Research (ECSR); 2021 September 23\u201325th; Berlin, Germany."},{"key":"2299_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2021.11.030","volume":"239","author":"Y Filts","year":"2022","unstructured":"Filts Y, Litman RE, Mart\u00ednez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM\u00ae in the treatment of schizophrenia: results from a 12-month open-label extension study. Schizophr Res. 2022;239:83\u201391.","journal-title":"Schizophr Res"},{"issue":"2","key":"2299_CR47","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","volume":"36","author":"AF Nasser","year":"2016","unstructured":"Nasser AF, Henderson DC, Fava M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase\u00a03 study. J Clin Psychopharmacol. 2016;36(2):130\u201340.","journal-title":"J Clin Psychopharmacol"},{"issue":"10202","key":"2299_CR48","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351.","journal-title":"Lancet"},{"key":"2299_CR49","unstructured":"European Medicine Angency. Committee for Medicinal Products for Human Use. Okedi Assessment report. EMA\/CHMP\/11233\/2022 rev.1, 16 December 2021. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/okedi-epar-public-assessment-report_en.pdf. Accessed  6 Jun 2022."},{"issue":"4","key":"2299_CR50","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.euroneuro.2005.10.006","volume":"16","author":"R Medori","year":"2006","unstructured":"Medori R, Mannaert E, Grunder G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol. 2006;16(4):233\u201340.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7\u20138","key":"2299_CR51","first-page":"17","volume":"9","author":"JJ Sheehan","year":"2012","unstructured":"Sheehan JJ, Reilly KR, Fu DJ, Alphs L. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 2012;9(7\u20138):17\u201323.","journal-title":"Innov Clin Neurosci"},{"issue":"3","key":"2299_CR52","first-page":"23","volume":"10","author":"A Wakamatsu","year":"2013","unstructured":"Wakamatsu A, Aoki K, Sakiyama Y, Ohnishi T, Sugita M. Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics. Innov Clin Neurosci. 2013;10(3):23\u201330.","journal-title":"Innov Clin Neurosci"},{"issue":"1","key":"2299_CR53","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.euroneuro.2017.11.009","volume":"28","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, de Leon J, Haen E, Stegmann B, Hiemke C, Grunder G, et al. Pharmacokinetics of risperidone in different application forms\u2014comparing long-acting injectable and oral formulations. Eur Neuropsychopharmacol. 2018;28(1):130\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2299_CR54","doi-asserted-by":"crossref","unstructured":"Ceraso A, Lin JJ, Schneider-Thoma J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020;8(8):CD008016.","DOI":"10.1002\/14651858.CD008016.pub3"},{"issue":"5","key":"2299_CR55","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","volume":"178","author":"G Ostuzzi","year":"2021","unstructured":"Ostuzzi G, Bertolini F, Del Giovane C, et al. Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis. Am J Psychiatry. 2021;178(5):424\u201336.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2299_CR56","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41467-017-00716-z","volume":"8","author":"DA Sykes","year":"2017","unstructured":"Sykes DA, Moore H, Stott L, et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat Commun. 2017;8(1):763.","journal-title":"Nat Commun"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02299-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02299-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T17:09:21Z","timestamp":1664557761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02299-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2299"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02299-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"12 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}